Q32 Bio and Horizon partner to develop autoimmune disease treatment
Pharmaceutical Technology
AUGUST 16, 2022
Q32 will also receive tiered royalty payments on net sales. Recently, Q32 concluded a Phase I clinical trial to evaluate the pharmacokinetics, pharmacodynamics and safety of ADX-914, which showed a pharmacological effect on T cells in healthy subjects. A fully human anti-IL-7R?
Let's personalize your content